Abstract
Experiments were designed to investigate a possible therapeutic role of interleukin-2 (IL-2) gene transfer in the model of murine (EL-4) leukaemia pretreated with cyclophosphamide. It has been found that i. p. pretreatment of the leukaemic mice with cyclophosphamide, followed by i. v. administration of irradiated cells, genetically engineered to produce IL-2 and used as a source of the cytokine (IR-IL-2 cells), cured a substantial percentage of the leukaemic mice. Neither treatment with cyclophosphamide nor administration of the IR-IL-2 cells alone had any significant therapeutic effect. Labelling of the EL-4 and IR-IL-2 cells with different fluorescent cell linkers followed by i. v. injection and detection of the labelled cells in cryostat sections of various organs has shown that both cell populations can be detected almost exclusively in the red pulp of the spleen, close to the white pulp nodules, thus providing the possibility of short-range local interactions among the IL-2-producing cells, IL-2-responsive defence effector cells and EL-4 leukaemia targets.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- IL-2:
-
interleukin-2
- IR-IL-2:
-
X63-m-IL-2 cells irradiated with 30 Gy
- IR-Ag8:
-
X63-Ag8.653 cells irradiated with 30 Gy
- EL-4:
-
murine transplantable T cell leukaemia
References
Bubeník J (1990) Local and regional immunotherapy of cancer with interleukin 2 (guest editorial). J Cancer Res Clin Oncol 116: 1–7
Bubeník J (1993) IL-2 and gene therapy of cancer (Review). Int J Oncol 2: 1049–1052
Bubeník J, Indrová M, Perlmann P, Berzins K, Mach O, Kraml J, Toulcová A (1985) Tumour-inhibitory effects of TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 19: 57–61
Bubeník J, Voitenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubeníková D, Šímová J, Jandlová T (1988) Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours innu/nu mice. Immunol Lett 19: 279–282
Bubeník J, Šímová J, Jandlová T (1990) Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 DNA and constitutively producing IL-2. Immunol Lett 23: 287–292
Bubeník J, Lotzová E, Indrová M, Šímová J, Jandlová T, Savary CA (1991) IL-2 gene transfer in immunotherapy of cancer: local administration of LAK and X63-m-IL-2 cells transformed by IL-2 cDNA and constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice. Nat Immun Cell Growth Regul 10: 247–255
Cheever MA, Greenberg PD, Gillis S, Fefer A (1982) Specific adoptive therapy of murine leukemia with cells sensitized in vitro and expanded by culture with interleukin 2. Prog Cancer Res Ther 22: 127–146
Foa R, Guarini A, Gansbacher B (1992) IL-2 treatment for cancer: from biology to gene therapy. Br J Cancer 66: 992–998
Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, Gilboa E, Golde D (1992) Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood 80: 2817–2825
Gorer PA, Amos DB (1956) Passive immunity of mice against C57BL leukosis EL-4 by means of iso-immune serum. Cancer Res 16: 338–343
Karasuyama H, Melchers F (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4, or 5 using modified cDNA expression vectors. Eur J Immunol 18: 97–104
Kearney JF, Radbruch A, Liesegang B, Rajewsky K (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123: 1548–1550
Kedar E, Klein E (1992) Cancer immunotherapy: are the results discouraging? Can they be improved? Adv Cancer Res 59: 245–322
Lee K, O'Donnell RW, Marquis D, Cockett ATK (1988) Eradication of palpable intradermal murine bladder tumours by systemic interleukin-2 and cyclophosphamide in C3H mice. J Biol Response Mod 7: 32–42
Naito K, Pellis NR, Kahan BD (1988) Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide. Cancer Res 48: 101–108
Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–484
Šímová J, Bubeník J, Voitenok NN, Gren E (1989) Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy. Folia Biol (Praha) 35: 137–142
Vallera DA, Taylor PA, Aukerman SL, Blazar BR (1993) Antitumor protection from the murine T-cell leukemia/lymphoma EL-4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Cancer Res 53: 4273–4280
Author information
Authors and Affiliations
Additional information
This work was supported by grants 312/93/0322 from the Grant Agency of the Czech Republic, 752103 from the Academy of Sciences of the Czech Republic and Z597-3 from the Grant Agency of the Ministry of Health of the Czech Republic
Rights and permissions
About this article
Cite this article
Bubeník, J., Šímová, J., Bubeníková, D. et al. Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J Cancer Res Clin Oncol 121, 39–43 (1995). https://doi.org/10.1007/BF01202727
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01202727